NCT01723839View on ClinicalTrials.gov

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 22, 2012

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
DRUG

Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.

Trial Locations (1)

07601

John Theurer Cancer Center at HackensackUMC, Hackensack

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Hackensack Meridian Health

OTHER

NCT01723839 - Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide | Biotech Hunter | Biotech Hunter